GoAI
Get started
HeartSciences Inc. logo

HeartSciences Inc.

HSCS

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.80

+$0.29 · +11.55%

Aug 21, 4:00 PM ET

Pre-market

$3.00

+$0.20 · +7.14%

Aug 24, 4:11 AM ET

HSCS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

45

Neutral

Sentiment

37

Bearish

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Andrew Simpson
Listed since
Jun 16, 2022
Employees
14

Market position

Day range

Current $2.80

52-week range

Current $2.80

Open
$2.575
Previous close
$2.51
Volume
198.81K
0.09× average
Average volume
2.3M
Average daily volume
Market cap
6.05M USD
Beta
1.8
Market reference 1
50-day average
$2.3729
+18.00% above average
200-day average
$2.5119
+11.47% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.28B USD
P/E (TTM)
-0.71×
P/B (TTM)
39.17×
P/S (TTM)
1,400×
EV / EBITDA
-271.6×
Earnings yield
-178.57%
Free cash flow yield
-145.93%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-2982.10%
Operating margin
-194787.38%
Net margin
-211666.47%
Return on equity
-4.05%
Return on assets
-0.17%
Return on invested capital
-0.20%

Financial health

Debt / equity
17.41×
Current ratio
0.53×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends21013%-63598%-148208%-232819%Gross margin, FY2022: -139.73%Gross margin, FY2023: -476.91%Gross margin, FY2024: -444.16%Gross margin, FY2025: -2884.71%Gross margin, FY2026: -2982.15%Operating margin, FY2022: -32765.60%Operating margin, FY2023: -118698.33%Operating margin, FY2024: -33901.99%Operating margin, FY2025: -192013.10%Operating margin, FY2026: -194787.38%Net margin, FY2022: -33592.57%Net margin, FY2023: -123384.27%Net margin, FY2024: -35511.87%Net margin, FY2025: -201499.52%Net margin, FY2026: -211666.47%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 -139.73%. Gross margin FY2023 -476.91%. Gross margin FY2024 -444.16%. Gross margin FY2025 -2884.71%. Gross margin FY2026 -2982.15%. Operating margin FY2022 -32765.60%. Operating margin FY2023 -118698.33%. Operating margin FY2024 -33901.99%. Operating margin FY2025 -192013.10%. Operating margin FY2026 -194787.38%. Net margin FY2022 -33592.57%. Net margin FY2023 -123384.27%. Net margin FY2024 -35511.87%. Net margin FY2025 -201499.52%. Net margin FY2026 -211666.47%.

Income trends

Revenue

4.32K USD-0.71%

Operating income

−8.41M USD-0.72%

Net income

−9.14M USD-4.30%
Income trends across reported periods934.65K USD−2.73M USD−6.39M USD−10.06M USDRevenue, FY2022: 14.37K USDRevenue, FY2023: 5.15K USDRevenue, FY2024: 18.6K USDRevenue, FY2025: 4.35K USDRevenue, FY2026: 4.32K USDOperating income, FY2022: −4.71M USDOperating income, FY2023: −6.11M USDOperating income, FY2024: −6.31M USDOperating income, FY2025: −8.35M USDOperating income, FY2026: −8.41M USDNet income, FY2022: −4.83M USDNet income, FY2023: −6.35M USDNet income, FY2024: −6.61M USDNet income, FY2025: −8.77M USDNet income, FY2026: −9.14M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 14.37K USD. Revenue FY2023 5.15K USD. Revenue FY2024 18.6K USD. Revenue FY2025 4.35K USD. Revenue FY2026 4.32K USD. Operating income FY2022 −4.71M USD. Operating income FY2023 −6.11M USD. Operating income FY2024 −6.31M USD. Operating income FY2025 −8.35M USD. Operating income FY2026 −8.41M USD. Net income FY2022 −4.83M USD. Net income FY2023 −6.35M USD. Net income FY2024 −6.61M USD. Net income FY2025 −8.77M USD. Net income FY2026 −9.14M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue4.32K USD4.35K USD18.6K USD5.15K USD14.37K USD
Cost of goods sold133.12K USD129.84K USD101.21K USD29.71K USD34.46K USD
Gross profit−128.8K USD−125.49K USD−82.61K USD−24.56K USD−20.08K USD
Research and development2.84B USD4.39M USD2.88M USD2.46M USD3M USD
Selling, general, and administrative5.58B USD3.84M USD3.34M USD3.63M USD1.69M USD
Operating expenses8.28M USD8.23M USD6.22M USD6.09M USD4.69M USD
Interest income—87.8K USD———
Interest expense753.04K USD500.45K USD354.08K USD243.17K USD371.62K USD
Depreciation and amortization—127.96K USD95.13K USD26.92K USD26.57K USD
Operating income−8.41M USD−8.35M USD−6.31M USD−6.11M USD−4.71M USD
Net income−9.14M USD−8.77M USD−6.61M USD−6.35M USD−4.83M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-1683.78%
11 comparable reports
Latest EPS result
-0.88
Estimate -0.66 · Miss by 33.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.54-1.27-2-2.73Q4 '24BeatQ1 '25MissQ3 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ3 '26MissQ3 '26Estimate
Q4 2024, reported Dec 16, 2024: actual -2.27, estimate -2.3, surprise +1.30%, Beat. Q1 2025, reported Mar 13, 2025: actual -2.57, estimate -2.53, surprise -1.58%, Miss. Q3 2025, reported Jul 24, 2025: actual -1.88, estimate -2.51, surprise +25.10%, Beat. Q3 2025, reported Sep 11, 2025: actual -1.58, estimate -2.41, surprise +34.44%, Beat. Q4 2025, reported Dec 15, 2025: actual -0.85, estimate -0.9, surprise +5.56%, Beat. Q1 2026, reported Mar 16, 2026: actual -0.63, estimate -0.84, surprise +25.00%, Beat. Q3 2026, reported Jul 23, 2026: actual -0.88, estimate -0.66, surprise -33.33%, Miss. Q3 2026, reported Sep 10, 2026: actual —, estimate -0.72, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates215.85K144.44K73.03K1.62KQ1 '24No estimateQ3 '24EstimateQ3 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26EstimateQ3 '26EstimateQ3 '26Estimate
Q1 2024, reported Mar 14, 2024: actual 14.7K USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Jul 29, 2024: actual —, estimate 50K USD, surprise —, Comparison unavailable. Q3 2025, reported Jul 24, 2025: actual 4.35K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 11, 2025: actual 1.9K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Dec 15, 2025: actual 2.42K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 16, 2026: actual —, estimate 200K USD, surprise —, Comparison unavailable. Q3 2026, reported Jul 23, 2026: actual —, estimate 50K USD, surprise —, Comparison unavailable. Q3 2026, reported Sep 10, 2026: actual —, estimate 100K USD, surprise —, Comparison unavailable.

HSCS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HSCS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
124.35K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research HSCS

research.disclaimer